<SEC-DOCUMENT>0001193125-25-263828.txt : 20251104
<SEC-HEADER>0001193125-25-263828.hdr.sgml : 20251104
<ACCEPTANCE-DATETIME>20251104104759
ACCESSION NUMBER:		0001193125-25-263828
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20251103
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251104
DATE AS OF CHANGE:		20251104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Metsera, Inc.
		CENTRAL INDEX KEY:			0002040807
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42489
		FILM NUMBER:		251447095

	BUSINESS ADDRESS:	
		STREET 1:		3 WORLD TRADE CENTER
		STREET 2:		175 GREENWICH STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10007
		BUSINESS PHONE:		(212) 784-6595

	MAIL ADDRESS:	
		STREET 1:		3 WORLD TRADE CENTER
		STREET 2:		175 GREENWICH STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10007
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d60790d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mtsr="http://metsera.com/20251103" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-448">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-11-03_to_2025-11-03">0002040807</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="mtsr-20251103.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-11-03_to_2025-11-03"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0002040807</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-03</xbrli:startDate> <xbrli:endDate>2025-11-03</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-459">8-K</ix:nonNumeric></span></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-11-03_to_2025-11-03" format="ixt:datemonthdayyearen" id="ixv-460">November 3, 2025</ix:nonNumeric></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-461">METSERA, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-11-03_to_2025-11-03" format="ixt-sec:stateprovnameen" id="ixv-462">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-463">001-42489</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-464">92-0931552</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(State or Other Jurisdiction<br/>of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr></table> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-465">3 World Trade Center</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-466">175 Greenwich Street</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-467">New York</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-11-03_to_2025-11-03" format="ixt-sec:stateprovnameen" id="ixv-468">New York</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-469">10007</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-470">212</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-471">784-6595</ix:nonNumeric></span></p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-11-03_to_2025-11-03" format="ixt-sec:boolballotbox" id="ixv-472">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-11-03_to_2025-11-03" format="ixt-sec:boolballotbox" id="ixv-473">&#9746;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-11-03_to_2025-11-03" format="ixt-sec:boolballotbox" id="ixv-474">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-11-03_to_2025-11-03" format="ixt-sec:boolballotbox" id="ixv-475">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-476">Common Stock, par value $0.00001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-477">MTSR</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-11-03_to_2025-11-03" format="ixt-sec:exchnameen" id="ixv-478">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#160;240.12b-2</span> of this chapter).</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-11-03_to_2025-11-03" format="ixt-sec:boolballotbox" id="ixv-479">&#9746;</ix:nonNumeric></p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2025-11-03_to_2025-11-03" format="ixt-sec:boolballotbox" id="ixv-480">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;8.01 Other Events </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On November&#160;4, 2025, Metsera, Inc., a Delaware corporation (the &#8220;Company&#8221; or &#8220;Metsera&#8221;), issued a press release announcing that on November&#160;4, 2025 the Metsera Board of Directors determined, after consultation with its outside counsel and financial advisors, that revised unsolicited proposal that Metsera received from Novo Nordisk A/S, a Danish aktieselskab&#160;(&#8220;Novo Nordisk&#8221;), on November 4, 2025, to acquire Metsera (the &#8220;a Novo Nordisk Proposal&#8221;) constitutes a &#8220;Superior Company Proposal&#8221; as defined in the Merger Agreement by and among Pfizer Inc. (&#8220;Pfizer&#8221;), a Delaware corporation, Mayfair Merger Sub, Inc. a Delaware corporation, and the Company (the &#8220;Pfizer Merger Agreement&#8221;). A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Revised Novo Nordisk Proposal </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of the Novo Nordisk Proposal are (in each case, as compared to the proposal made by Novo Nordisk on October&#160;25, 2025 and as described in the previously filed Current Report on Form <span style="white-space:nowrap">8-K</span> filed by the Company on October&#160;30, 2025 with the SEC (the &#8220;October 25 Novo Nordisk Proposal&#8221;): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">i.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">increasing the amount that a Novo Nordisk subsidiary would pay to Metsera from $56.50 per Metsera common share in cash to $62.20 per Metsera common share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">ii.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">increasing the dividend that Metsera would declare from $56.50 per Metsera common share, in cash, to $62.20 per Metsera common share, with a record date ten days following the signing the definitive agreements relating to the Novo Proposal with payment to follow in the days shortly thereafter; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">iii.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">increasing the maximum amount payable under the <span style="white-space:nowrap">non-transferable</span> contingent value right (&#8220;CVR&#8221;) from up to $21.25 to up to $24.00 per share of Company Common Stock in cash, as follows: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">a.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Clinical Trial Milestone</span></span>: From $4.75 to $5.25 per CVR following the Phase 3 clinical trial start of the Company&#8217;s <span style="white-space:nowrap">MET-097i</span> and <span style="white-space:nowrap">MET-233i</span> combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">b.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Mono FDA Approval Milestone</span></span>: From $6.50 to $7.50 per CVR following U.S. Food and Drug Administration (FDA) approval of the Company&#8217;s monthly <span style="white-space:nowrap">MET-097i</span> monotherapy; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">c.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Combination FDA Approval Milestone</span></span>: $10.00 to $11.25 per CVR following FDA approval of the Company&#8217;s monthly <span style="white-space:nowrap">MET-097i</span> and <span style="white-space:nowrap">MET-233i</span> combination. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Revised Novo Nordisk Proposal expires at 10.00 a.m. Eastern Time on November 6, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Novo Nordisk Proposal is not complete and is qualified in its entirety by reference to the Novo Irrevocable Offer, which is attached as Exhibit 99.2 to this report and incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Receipt of Revised Pfizer Proposal </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;3, 2025, Metsera received a proposal (the &#8220;Revised Pfizer Proposal&#8221;) from Pfizer, Inc. (&#8220;Pfizer&#8221;) to amend the existing Agreement and Plan of Merger, dated as of September&#160;21, 2025, by and among Metsera, Inc. (the &#8220;Company&#8221;), Pfizer and Mayfair Merger Sub, Inc. (the &#8220;Merger Agreement&#8221;) on the following material terms (in each case, as compared to the Pfizer Merger Agreement): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">i.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">increasing the cash consideration to be paid by Pfizer from $47.50 to $60.00 in cash per share of Company Common Stock, without interest; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">ii.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">decreasing the maximum amount payable under the <span style="white-space:nowrap">non-transferable</span> contingent value right (&#8220;CVR&#8221;) from up to $22.50 to up to $10.00 per share of Company Common Stock in cash, as follows: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">a.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Clinical Trial Milestone</span></span>: From $5.00 to $2.75 per CVR following the Phase 3 clinical trial start of the Company&#8217;s <span style="white-space:nowrap">MET-097i</span> and <span style="white-space:nowrap">MET-233i</span> combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">b.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Mono FDA Approval Milestone</span></span>: From $7.00 to $4.25 per CVR following U.S. Food and Drug Administration (FDA) approval of the Company&#8217;s monthly <span style="white-space:nowrap">MET-097i</span> monotherapy; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">c.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Combination FDA Approval Milestone</span></span>: From $10.50 to $3.00 per CVR following FDA approval of the Company&#8217;s monthly <span style="white-space:nowrap">MET-097i</span> and <span style="white-space:nowrap">MET-233i</span> combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">iii.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">amending the commercially reasonable efforts obligations set forth in the CVR Agreement to match the terms proposed by Novo Nordisk in the October&#160;25 Novo Proposal; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">iv.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">agreeing with a shareholder of Metsera to sell Pfizer 14.9% of the common stock of Metsera upon signing of the transaction; and </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">v.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Metsera to issue a press release stating that the Novo Nordisk Proposal presented unacceptably high risks and was unviable. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;29, 2025, Pfizer made a proposal to amend the Merger Agreement on the following material terms (i)&#160;an increase in the Closing amount from $47.50 to $50.50 and (ii)&#160;a term substantially similar to that described in (v)&#160;above. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Board Recommendation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At this time, the Merger Agreement remains in full effect, and Metsera&#8217;s Board of Directors reaffirm their recommendation that the holders of Metsera common stock approve the adoption of the Merger Agreement and approve the Merger with Pfizer on the terms and subject to the conditions set forth in the Merger Agreement. However, no action by Metsera shareholders is required at this time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Federal Tax Treatment of the Dividend </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Metsera does not believe it has a meaningful amount of &#8220;earnings and profits&#8221;.&#160;As such, Metsera currently expects that, for U.S. federal tax purposes, the Dividend will be treated first, as a return of capital to shareholders to the extent of their tax basis in their Metsera&#160;common stock, and thereafter as capital gain from the sale or exchange of Metsera stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ultimate tax treatment of the Dividend will be based on Metsera&#8217;s current and accumulated earnings and profits for Metsera&#8217;s year ending December&#160;31, 2025. The process of determining current and accumulated earnings and profits requires a final determination of Metsera&#8217;s financial results for the year and a review of certain other factors. Accordingly, the expected tax treatment of the Dividend is based upon currently available information and is subject to change. Metsera expects to update information on the taxation of the Dividend following the completion of 2025.&#160;To the extent Metsera has current or accumulated earnings and profits, as determined under U.S. federal income tax principles, the Dividend will be treated as a dividend that is, for U.S. holders that are individuals, &#8220;qualified dividend income&#8221; subject to U.S. federal income tax at the lower applicable long-term capital gains rates, provided certain holding period requirements are satisfied. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because Metsera&#8217;s current and accumulated earnings and profits for Metsera&#8217;s year ending December&#160;31, 2025 cannot yet be finally determined, Metsera expects that withholding agents will withhold on the Dividend paid to <span style="white-space:nowrap">non-U.S.</span> holders at a rate of 30% (or such lower rate specified by an applicable income tax treaty). Following the completion of the earnings and profits analysis, <span style="white-space:nowrap">non-U.S.</span> holders may seek refunds from the Internal Revenue Service of any amounts overwithheld. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The finally determined tax treatment of the Dividend as reported on Form 8937 will be available on Metsera&#8217;s website. The Form 8937 will be updated following the determination of Metsera&#8217;s financial results for the year ended December&#160;31, 2025 and a review of certain other factors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth above is provided only for general use, and does not constitute a complete description of all of the U.S. federal tax consequences of the receipt of the Dividend or the ownership and disposition of Metsera&#8217;s common stock. Shareholders should consult their own tax advisors concerning such consequences. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;9.01 Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold">Exhibit<br/>No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d60790dex991.htm">Press Release, dated as of November&#160;4, 2025. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d60790dex992.htm">Novo Irrevocable Offer, dated as of November&#160;4, 2025. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Forward Looking Statements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">This release contains forward-looking information about, among other topics, Pfizer&#8217;s proposed acquisition of Metsera, Pfizer&#8217;s and Metsera&#8217;s pipeline products, including their potential benefits, potential <span style="white-space:nowrap"><span style="white-space:nowrap">best-in-class</span></span> status, differentiation, profile and dosing, potential clinical trials, and the anticipated timing of completion of the proposed acquisition, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties relating to Pfizer&#8217;s proposed acquisition of Metsera include, among other things, risks related to the satisfaction or waiver of the conditions to closing the proposed acquisition (including the failure to obtain necessary regulatory approvals and failure to obtain the requisite vote by Metsera stockholders) in the anticipated timeframe or at all, including the possibility that the proposed acquisition does not close; the possibility that more competing offers may be made; risks related to the ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the transaction making it more difficult to maintain business and operational relationships, including Metsera&#8217;s ability to attract and retain highly qualified management and other clinical and scientific personnel; negative effects of this announcement or the consummation of the proposed acquisition on the market price of Pfizer&#8217;s or Metsera&#8217;s common stock and/or operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the proposed acquisition, including expenses from defending the litigation, potential damages or other losses resulting from the litigation, the impact of the litigation on the Company, its business and the market price of the Company&#8217;s common stock; other business effects and uncertainties, including the effects of industry, market, business, economic, political or regulatory conditions; future exchange and interest rates; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws, regulations or policy; changes in tax and other laws, regulations, rates and policies; the uncertainties inherent in business and financial planning, including, without limitation, risks related to Pfizer&#8217;s business and prospects, adverse developments in Pfizer&#8217;s markets, or adverse developments in the U.S. or global capital markets, credit markets, regulatory environment, tariffs and other trade policies or economies generally; future business combinations or disposals; uncertainties regarding the commercial success of Metsera&#8217;s pipeline products or Pfizer&#8217;s commercialized and/or pipeline products; risks associated with Metsera conducting clinical trials and preclinical studies outside of the United States; Metsera&#8217;s reliance on third parties to conduct clinical trials and preclinical studies and for the manufacture and shipping of its product candidates; the risk that Metsera&#8217;s product candidates are associated with side effects, adverse events or other properties or safety risks; risks associated with Metsera&#8217;s license and collaboration agreements and future strategic alliances; Metsera&#8217;s ability to obtain, maintain, defend and enforce patent or other intellectual property protection for current or future product candidates or technology; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with initial, preliminary or interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; whether and when drug applications may be filed in any jurisdictions for Pfizer&#8217;s or Metsera&#8217;s pipeline products for any potential indications; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product&#8217;s benefits outweigh its known risks and determination of the product&#8217;s efficacy and, if approved, whether any such products will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of such products; uncertainties regarding the impact of <span style="white-space:nowrap">COVID-19;</span> and competitive developments. </span></p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">You should carefully consider the foregoing factors and the other risks and uncertainties that affect the businesses of Pfizer and Metsera described in the &#8220;Risk Factors&#8221; and &#8220;Forward-Looking Information and Factors That May Affect Future Results&#8221; (in the case of Pfizer) and &#8220;Special Note regarding Forward Looking Statements&#8221; (in the case of Metsera) sections of their respective Annual Reports on Form <span style="white-space:nowrap">10-K,</span> Quarterly Reports on Form <span style="white-space:nowrap">10-Q</span> and other documents filed by either of them from time to time with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), all of which are available at <span style="text-decoration:underline">www.sec.gov</span>. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Pfizer and Metsera assume no obligation to, and do not intend to, update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. Neither Pfizer nor Metsera gives any assurance that it will achieve its expectations. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Additional Information and Where to Find It </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">In connection with Pfizer&#8217;s proposed acquisition of Metsera, Metsera has filed documents with the SEC, including preliminary and definitive proxy statements relating to the proposed transaction. The definitive proxy statement has been mailed to Metsera&#8217;s stockholders in connection with the proposed transaction. This communication is not a substitute for the proxy statement or any other document that may be filed by Metsera with the SEC. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PRELIMINARY AND DEFINITIVE PROXY STATEMENTS AND ANY OTHER DOCUMENTS THAT HAVE BEEN OR WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Any vote in respect of resolutions to be proposed at Metsera&#8217;s stockholder meeting to approve the proposed transaction or other responses in relation to the proposed transaction should be made only on the basis of the information contained in Metsera&#8217;s proxy statement. Investors and security holders may obtain free copies of these documents and other related documents filed with the SEC at the SEC&#8217;s web site at <span style="text-decoration:underline">www.sec.gov</span>, or at <span style="text-decoration:underline">www.metsera.com</span>. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">No Offer or Solicitation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Participants in the Solicitation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Metsera and its directors, executive officers and other members of management and employees, under SEC rules, may be deemed to be &#8220;participants&#8221; in the solicitation of proxies from stockholders of Metsera in favor of the proposed transaction. Information about Metsera&#8217;s directors and executive officers is set forth in Part III of Metsera&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the fiscal year ended December&#160;31, 2024, which was filed with the SEC on March&#160;26, 2025. Additional information concerning the interests of Metsera&#8217;s participants in the solicitation, which may, in some cases, be different than those of Metsera&#8217;s stockholders generally, will be set forth in Metsera&#8217;s proxy statement relating to the proposed transaction when it becomes available. These documents are available free of charge at the SEC&#8217;s web site at <span style="text-decoration:underline">www.sec.gov</span> and at <span style="text-decoration:underline">www.metsera.com</span>. </span></p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold">METSERA, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: November&#160;4, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Matthew Lang</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Matthew Lang</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Chief Legal Officer and Secretary</span></p></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d60790dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Metsera Receives Amended Proposal from Novo Nordisk </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Metsera Declares Novo Nordisk Amended Proposal &#8220;Superior&#8221; </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Novo Nordisk Amended Proposal Values Metsera at up to $86.20 per Share, a Total of Approximately $10.0 Billion </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Superior to Revised Pfizer Proposal that Valued Metsera at up to $70.00 per Share, a Total of Approximately $8.1 Billion </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Pursuant to Pfizer Merger Agreement, Metsera and Pfizer May Negotiate Potential Adjustments for Two Business Days </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Pfizer Merger Agreement Remains in Effect; No Action Required by Metsera Shareholders </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;4, 2025&#8212;Metsera, Inc. (NASDAQ: MTSR) (&#8220;Metsera&#8221;) today announced that its Board of Directors had determined, after
consultation with its outside counsel and financial advisors, that a revised proposal that Metsera received from Novo Nordisk A/S (Nasdaq Copenhagen: NOVO B) (&#8220;Novo Nordisk&#8221;) to acquire Metsera (the &#8220;Novo Nordisk Amended
Proposal&#8221;) constitutes a &#8220;Superior Company Proposal&#8221; as defined in Metsera&#8217;s existing Merger Agreement with Pfizer (the &#8220;Pfizer Merger Agreement&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novo Nordisk&#8217;s Proposal is structured in two steps. In the first step, immediately following the signing of a definitive agreement, Novo Nordisk would
pay Metsera $62.20 per Metsera common share in cash (up from $56.50) as well as certain amounts in respect of Metsera employee equity and transaction expenses. In exchange, Metsera would issue Novo Nordisk
<FONT STYLE="white-space:nowrap">non-voting</FONT> preferred stock representing 50% of Metsera&#8217;s share capital. Shortly thereafter, Metsera would declare a dividend (the &#8220;Dividend&#8221;) of $62.20 per Metsera common share in cash (up
from $56.50), with a record date ten days following the signing of the definitive agreements relating to the Novo Nordisk Amended Proposal, with payment to follow shortly thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the second step, which would happen only after receiving approval from Metsera shareholders and relevant regulators, Metsera shareholders would receive a
contingent value right (&#8220;CVR&#8221;) representing up to $24.00 per share in cash (up from $21.25) based on development and regulatory approval milestones the same as those agreed in the proposed merger between Metsera and Pfizer, and Novo
Nordisk would acquire the remainder of the outstanding shares of Metsera. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proposal values Metsera at up to $86.20 per share, for a total of
approximately $10.0&nbsp;billion, representing an approximate 159% premium to Metsera&#8217;s closing price as of September&nbsp;19, 2025, the last trading day before the Pfizer transaction was announced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Metsera today notified Pfizer of its declaration of the Novo Nordisk Amended Proposal as a &#8220;Superior Company Proposal&#8221;. Under the terms of the
Pfizer Merger Agreement, this notice (the &#8220;Notice&#8221;) triggers a two business day period during which Pfizer has the right to negotiate with Metsera adjustments to the terms and conditions of the Pfizer Merger Agreement so that the Novo
Nordisk Amended Proposal would cease to constitute a &#8220;Superior Company Proposal&#8221;. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the conclusion of this period, if Metsera&#8217;s Board of Directors concludes in good faith,
after consultation with its outside counsel and financial advisors, that, after considering any adjustments to the terms of the Pfizer Merger Agreement proposed by Pfizer, the Novo Nordisk Amended Proposal continues to constitute a &#8220;Superior
Company Proposal&#8221;, Metsera would be entitled to terminate the Pfizer Merger Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revised Pfizer Proposal </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Metsera&#8217;s determination takes into account a proposal made by Pfizer on November&nbsp;3, 2025, that increased the upfront consideration to $60.00 per
share in cash (up from $47.50) and decreased the amount payable under the CVR to up to $10.00 per share in cash (down from $22.50). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the
Revised Pfizer Proposal (i)&nbsp;adopted the same commercially reasonable efforts standard for the CVR as in the Novo Nordisk Proposal, (ii)&nbsp;required a shareholder of Metsera to sell Pfizer 14.9% of the common stock of Metsera upon signing of
the transaction and (iii)&nbsp;required Metsera to issue a press release stating that the Novo Nordisk Proposal presented unacceptably high risks and was unviable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board Recommendation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At this time, the Pfizer
Merger Agreement remains in full effect, and Metsera&#8217;s Board of Directors reaffirm their recommendation that the holders of Metsera common stock approve the adoption of the Pfizer Merger Agreement and approve the Merger with Pfizer on the
terms and subject to the conditions set forth in the Pfizer Merger Agreement. However, no action by Metsera shareholders is required at this time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U</B><B><I>.S. Federal Tax Treatment of the Dividend</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Metsera does not believe it has a meaningful amount of &#8220;earning and profits&#8221;. As such, Metsera currently expects that, for U.S. federal tax
purposes, the Dividend will be treated first, as a return of capital to shareholders to the extent of their tax basis in their Metsera common stock, and thereafter as capital gain from the sale or exchange of Metsera stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ultimate tax treatment of the Dividend will be based on Metsera&#8217;s current and accumulated earnings and profits for Metsera&#8217;s year ending
December&nbsp;31, 2025. The process of determining current and accumulated earnings and profits requires a final determination of Metsera&#8217;s financial results for the year and a review of certain other factors. Accordingly, the expected tax
treatment of the Dividend is based upon currently available information and is subject to change. Metsera expects to update information on the taxation of the Dividend following the completion of 2025. To the extent Metsera has current or
accumulated earnings and profits, as determined under U.S. federal income tax principles, the Dividend will be treated as a dividend that is, for U.S. holders that are individuals, &#8220;qualified dividend income&#8221; subject to U.S. federal
income tax at the lower applicable long-term capital gains rates, provided certain holding period requirements are satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because Metsera&#8217;s
current and accumulated earnings and profits for Metsera&#8217;s year ending December&nbsp;31, 2025 cannot yet be finally determined, Metsera expects that withholding agents will withhold on the Dividend paid to
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders at a rate of 30% (or such lower rate specified by an applicable income tax treaty). Following the completion of the earnings and profits analysis,
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders may seek refunds from the Internal Revenue Service of any amounts overwithheld. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The finally determined tax treatment of the Dividend as reported on Form 8937 will be available on
Metsera&#8217;s website. The Form 8937 will be updated following the determination of Metsera&#8217;s financial results for the year ended December&nbsp;31, 2025 and a review of certain other factors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth above is provided only for general use, and does not constitute a complete description of all of the U.S. federal tax consequences
of the receipt of the Dividend or the ownership and disposition of Metsera&#8217;s common stock. Shareholders should consult their own tax advisors concerning such consequences. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disclosure Notice </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This release contains
forward-looking information about, among other topics, Pfizer&#8217;s proposed acquisition of Metsera, Pfizer&#8217;s and Metsera&#8217;s pipeline products, including their potential benefits, potential <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> status, differentiation, profile and dosing, potential clinical trials, and the anticipated timing of completion of the proposed acquisition, that involves substantial risks and uncertainties
that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties relating to Pfizer&#8217;s proposed acquisition of Metsera include, among other things, risks relating to Pfizer&#8217;s
litigation against the Company, including expenses from defending the litigation, potential damages or other losses resulting from the litigation, the impact of the litigation on the Company, its business and the market price of the Company&#8217;s
common stock and the impact of the litigation on Novo Nordisk&#8217;s unsolicited proposal, risks related to the satisfaction or waiver of the conditions to closing the proposed acquisition (including the failure to obtain necessary regulatory
approvals and failure to obtain the requisite vote by Metsera stockholders) in the anticipated timeframe or at all, including the possibility that the proposed acquisition does not close; the possibility that more competing offers may be made; risks
related to the ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk
that the businesses will not be integrated successfully; disruption from the transaction making it more difficult to maintain business and operational relationships, including Metsera&#8217;s ability to attract and retain highly qualified management
and other clinical and scientific personals; negative effects of this announcement or the consummation of the proposed acquisition on the market price of Pfizer&#8217;s or Metsera&#8217;s common stock and/or operating results; significant
transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the proposed acquisition or Metsera&#8217;s business; other business effects and uncertainties, including the effects of industry, market, business,
economic, political or regulatory conditions; future exchange and interest rates; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws, regulations or policy; changes in tax and other laws,
regulations, rates and policies; the uncertainties inherent in business and financial planning, including, without limitation, risks related to Pfizer&#8217;s business and prospects, adverse developments in Pfizer&#8217;s markets, or adverse
developments in the U.S. or global capital markets, credit markets, regulatory environment, tariffs and other trade policies or economies generally; future business combinations or disposals; uncertainties regarding the commercial success of
Metsera&#8217;s pipeline products or Pfizer&#8217;s commercialized and/or pipeline products; risks associated with Metsera conducting clinical trials and preclinical studies outside of the United
</I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
States; Metsera&#8217;s reliance on third parties to conduct clinical trials and preclinical studies and for the manufacture and shipping of its product candidates; the risk that Metsera&#8217;s
product candidates are associated with side effects, adverse events or other properties or safety risks; risks associated with Metsera&#8217;s license and collaboration agreements and future strategic alliances; Metsera&#8217;s ability to obtain,
maintain, defend and enforce patent or other intellectual property protection for current or future product candidates or technology; the uncertainties inherent in research and development, including the ability to meet anticipated clinical
endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical
data; risks associated with initial, preliminary or interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design
of and results from the clinical studies; whether and when drug applications may be filed in any jurisdictions for Pfizer&#8217;s or Metsera&#8217;s pipeline products for any potential indications; whether and when any such applications may be
approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product&#8217;s benefits outweigh its known risks and determination of the product&#8217;s efficacy and, if approved, whether
any such products will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of such products;
uncertainties regarding the impact of <FONT STYLE="white-space:nowrap">COVID-19;</FONT> and competitive developments. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>You should carefully
consider the foregoing factors and the other risks and uncertainties that affect the businesses of Pfizer and Metsera described in the &#8220;Risk Factors&#8221; and &#8220;Forward-Looking Information and Factors That May Affect Future
Results&#8221; (in the case of Pfizer) and &#8220;Special Note regarding Forward Looking Statements&#8221; (in the case of Metsera) sections of their respective Annual Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,&nbsp;Quarterly</FONT>
Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q&nbsp;and</FONT> other documents filed by either of them from time to time with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), all of which are available
at&nbsp;<U>www.sec.gov</U>. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements
speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Pfizer and Metsera assume no obligation to, and do not intend to, update or revise these forward-looking statements, whether
as a result of new information, future events, or otherwise, unless required by law. Neither Pfizer nor Metsera gives any assurance that it will achieve its expectations. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional Information and Where to Find It </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In
connection with Pfizer&#8217;s proposed acquisition of Metsera, Metsera has filed documents with the SEC, including preliminary and definitive proxy statements relating to the proposed transaction. The definitive proxy statement has been mailed to
Metsera&#8217;s stockholders in connection with the proposed transaction. This communication is not a substitute for the proxy statement or any other document that may be filed by Metsera with the SEC. BEFORE MAKING ANY VOTING DECISION, INVESTORS
AND SECURITY HOLDERS ARE URGED TO READ THE PRELIMINARY AND DEFINITIVE PROXY STATEMENTS AND ANY OTHER DOCUMENTS THAT HAVE BEEN OR WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN
OR WILL CONTAIN </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Any vote in respect of resolutions to be proposed at Metsera&#8217;s stockholder meeting to approve the proposed transaction or other
responses in relation to the proposed transaction should be made only on the basis of the information contained in Metsera&#8217;s proxy statement. Investors and security holders may obtain free copies of these documents and other related documents
filed with the SEC at the SEC&#8217;s web site at&nbsp;<U>www.sec.gov</U>, or at&nbsp;<U>www.metsera.com</U>. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Offer or Solicitation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or
the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or
otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Participants
in the Solicitation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Metsera and its directors, executive officers and other members of management and employees, under SEC rules, may be deemed
to be &#8220;participants&#8221; in the solicitation of proxies from stockholders of Metsera in favor of the proposed transaction. Information about Metsera&#8217;s directors and executive officers is set forth in Part III of Metsera&#8217;s Annual
Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the fiscal year ended December&nbsp;31, 2024, which was filed with the SEC on March&nbsp;26, 2025. Additional information concerning the interests of Metsera&#8217;s
participants in the solicitation, which may, in some cases, be different than those of Metsera&#8217;s stockholders generally, is set forth in Metsera&#8217;s proxy statement relating to the proposed transaction. These documents are available free
of charge at the SEC&#8217;s web site at&nbsp;<U>www.sec.gov</U>&nbsp;and at&nbsp;<U>www.metsera.com</U>. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Press Contact </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teneo </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TJ White </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Tj.white@teneo.com </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(929)
<FONT STYLE="white-space:nowrap">736-3795</FONT> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d60790dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g60790g1104193305380.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November 4, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Board of
Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Metsera, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3 World Trade Center </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">175 Greenwich Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10007 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Reference is made to that
certain Agreement and Plan of Merger, dated as of September&nbsp;21, 2025, by and among Pfizer Inc., a Delaware corporation (&#8220;<U>Pfizer</U>&#8221;), Mayfair Merger Sub, Inc., a wholly owned subsidiary of Pfizer and a Delaware corporation
(&#8220;<U>Mayfair Merger Sub</U>&#8221;), and Metsera, Inc., a Delaware corporation (&#8220;<U>Metsera</U>&#8221;) (the &#8220;<U>Pfizer Merger Agreement</U>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Novo Nordisk A/S, a Danish <I>aktieselskab </I>(&#8220;<U>Parent</U>&#8221;), NN US Invest, Inc., a Delaware corporation and a wholly owned
Subsidiary of Parent (&#8220;<U>Sub</U>&#8221;), and Novo Nordisk US Research Investments Holdings, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (&#8220;<U>Investor Sub</U>&#8221;) (Sub, Investor Sub and Parent together, the
&#8220;<U>Purchasers</U>&#8221; or &#8220;<U>we</U>&#8221;) are pleased to make this irrevocable and legally binding offer, subject to the terms and conditions set forth herein, (the &#8220;<U>Parent Offer</U>&#8221;) to (A)&nbsp;acquire 100% of the
issued and outstanding equity interests of Metsera for $62.20 per share in cash and up to an additional $24.00 per share in cash upon achievement of the agreed contingent value right milestones (specifically, (i) $5.25 per share in cash upon the
achievement of the clinical trial milestone, (ii) $7.50 per share in cash upon the achievement of the mono FDA approval milestone and (iii) $11.25 per share in cash upon the achievement of the combination FDA approval milestone) and (B)&nbsp;in
furtherance of clause (A), enter into (i)&nbsp;the Agreement and Plan<U> of Merger (the &#8220;Parent M</U>erger Agreement&#8221;), by and among Parent, Sub, Investor Sub and Metsera, (ii)&nbsp;the Voting and Support Agreement (the <U>&#8220;Voting
and Support</U> Agreement&#8221;), by and among Parent, V<U>alidae H</U>ealth, L.P. (&#8220;Validae&#8221;), Population Health P<U>artne</U>rs GP, LLC (&#8220;PHP&#8221;), ARCH Ventu<U>re Fund X</U>II, L.P. (&#8220;Arch XII&#8221;), and ARCH Venture
Fund XIII, L.P. (together with Validae, PHP, and<U> Arch XII, th</U>e &#8220;Shareholders&#8221;) and (iii)&nbsp;the Registration Rights Agre<U>ement (the &#8220;Registration Right</U>s Agreement&#8221;), by and among Metsera, Investor Sub and any
transfer recipient thereto, in each case in the form previously submitted by Parent to Metsera in the prior irrevocable offer letter, dated as of October&nbsp;30, 2025, <I>mutatis mutandis </I>(giving effect to the revised terms set forth herein).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Parent Offer (and the enclosed executed signature pages to the Parent Merger Agreement, the Voting and Support Agreement and the
Registration Rights Agreement) will remain open and irrevocable by the Purchasers for acceptance by Metsera concurrently with or following the termination of the Pfizer Merger Agreement by duly executing and delivering the Parent Merger Agreement
and the Registration Rights Agreement (and causing the Shareholders to duly execute and deliver the Voting and Support Agreement) to the Purchasers until twenty-four hours following the termination of the Pfizer Merger Agreement in accordance with
its terms (the period from the date of this letter to such time, the &#8220;<U>Offer Period</U>&#8221;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary herein, the Parent Offer (and the enclosed executed
signature pages to the Parent Merger Agreement, the Voting and Support Agreement and the Registration Rights Agreement) will be automatically withdrawn and revoked and shall automatically be void and of no further force or effect: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if Metsera fails to determine the Parent Offer is a Superior Company Proposal (as defined in the Pfizer Merger
Agreement) in accordance with the Pfizer Merger Agreement within twenty-four hours of Metsera&#8217;s receipt of this letter; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if Metsera fails to accept the Parent Offer concurrently with or following the termination of the Pfizer Merger
Agreement by 10:00 a.m. on November 6, 2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(A)&nbsp;if Metsera does not return to the Purchasers a fully executed and delivered Parent Merger Agreement
and Registration Rights Agreement by delivering a validly signed signature page to (x)&nbsp;the Parent Merger Agreement and (y)&nbsp;the Registration Rights Agreement, in each case, that is legally binding on Metsera and (B)&nbsp;if the Shareholders
do not return to the Purchasers fully executed and delivered Voting and Support Agreement that are legally binding on the Shareholders, in each case prior to the expiration of the Offer Period; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">upon (x)&nbsp;the effectiveness of any amendment or modification to the Pfizer Merger Agreement or (y)&nbsp;the
grant of any consent or waiver under the Pfizer Merger Agreement that has the effect of permitting Metsera to pay any dividend or repurchase any shares of capital stock or otherwise improves the financial terms of the transaction contemplated by the
Pfizer Merger Agreement from the perspective of Metsera stockholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Purchasers represents that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the board of directors of Parent and Investor Sub has approved and declared advisable (1) the Parent Merger
Agreement, the Merger (as defined in the Parent Merger Agreement) and the Transactions (as defined in the Parent Merger Agreement) and (2) determined that it is in the best interests of Parent and Investor Sub, respectively, to enter into the Parent
Merger Agreement and consummate the Merger and the other Transactions on the terms and subject to the conditions set forth in the Parent Merger Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the board of directors of Sub has (1)&nbsp;unanimously approved and declared advisable the Parent Merger
Agreement, the Merger and the other Transactions, (2)&nbsp;directed that the adoption of the Parent Merger Agreement be submitted to the sole stockholder of Sub and (3)&nbsp;recommended that the Parent Merger Agreement be adopted by the sole
stockholder of Sub; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Parent, Sub, and the Investor Sub are duly authorized by all necessary organizational action and no other
organizational proceedings on the part of Parent, Sub or the Investor Sub are necessary to authorize the Parent Merger Agreement, to perform their respective obligations under the Parent Merger Agreement or to consummate the Merger and the other
Transactions, subject, in the case of the consummation of the Merger, to the adoption of the Parent Merger Agreement by the sole stockholder of Sub; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(x)&nbsp;the Parent Merger Agreement has been duly executed and delivered by Parent, Sub and Investor Sub, and
(y), assuming the due authorization, execution and delivery of the Parent Merger Agreement by Metsera, constitutes the legal, valid and binding obligation of Parent, Sub and Investor Sub, enforceable against Parent, Sub and Investor Sub in
accordance with its terms, subject to the Bankruptcy Exceptions (as defined in the Parent Merger Agreement); </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of
the Purchasers agrees that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">neither this letter nor the Parent Offer will be revoked, terminated, withdrawn, modified or amended prior to
the expiration of the Offer Period in violation of the terms of this letter without Metsera&#8217;s express prior written consent and acknowledges that Metsera is relying upon this letter and the Parent Offer and that irreparable damage would occur
if this letter or the Parent Offer were revoked, terminated, withdrawn, modified or amended prior to the expiration of the Offer Period or otherwise in violation of the terms of this letter; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Metsera shall be entitled to injunctive relief to prevent any purported revocation, withdrawal, modification or
amendment of the Parent Offer, without Metsera&#8217;s prior written consent, prior to the expiration of the Offer Period and to enforce specifically the terms and provisions of the Parent Offer in the Court of Chancery of the State of Delaware in
and for New Castle County, Delaware (or, if (and only if) such court finds it lacks subject matter jurisdiction, the federal court of the United States of America sitting in Delaware, and appellate courts thereof, or, if (and only if) each of such
Court of Chancery for the State of Delaware and such federal court finds it lacks subject matter jurisdiction, any state court within the State of Delaware), this being in addition to any other remedy at law or in equity, and each of the Purchasers
hereby waives any requirement for the posting of any bond or similar collateral in connection therewith, it being understood that this clause (ii)&nbsp;and the foregoing clause (i)&nbsp;shall survive any termination of this letter or the Parent
Offer and no such termination shall relieve the Purchasers from any liability or obligation under such provisions and nothing contained herein shall relieve any party from liability for any Willful Breach (as defined in the Parent Merger Agreement)
hereof. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms and provisions of Sections 9.02 (Notices), 9.03 (Definitions), 9.06 (Entire Agreement; No Third-Party
Beneficiaries), 9.07 (Governing Law), 9.08 (Assignment), 9.09 (Consent to Jurisdiction; Service of Process; Venue) and 9.10 (Waiver of Jury Trial), and 9.11 (Enforcement) of the Parent Merger Agreement are incorporated herein by reference as if set
forth herein in their entirety and shall apply <I>mutatis mutandis </I>to this letter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely yours,</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Novo Nordisk A/S</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000;">/s/ Mike Doustdar</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mike Doustdar</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page &#8211; Irrevocable Binding Offer Letter</I>] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>mtsr-20251103.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/4/2025 8:39:43 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:mtsr="http://metsera.com/20251103"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://metsera.com/20251103"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mtsr-20251103_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mtsr-20251103_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>mtsr-20251103_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/4/2025 8:39:43 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>mtsr-20251103_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/4/2025 8:39:44 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="mtsr-20251103.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g60790g1104193305380.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g60790g1104193305380.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  U $H# 2(  A$! Q$!_\0
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M^H'>MG5-;T;4O!5S?72S2:=,ABEC52),YVE,=0<\4 96D>/+"V^%ECXDOI0
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DX?U/3)[>?<FJR7$%W&4X9D9W1U.>"!E2.AX/!KTG-%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 03, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0002040807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  03,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">METSERA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-42489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">92-0931552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3 World Trade Center<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">175 Greenwich Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">784-6595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.00001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MTSR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d60790d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d60790d8k.htm">d60790d8k.htm</File>
    <File>mtsr-20251103.xsd</File>
    <File>mtsr-20251103_lab.xml</File>
    <File>mtsr-20251103_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d60790d8k.htm": {
   "nsprefix": "mtsr",
   "nsuri": "http://metsera.com/20251103",
   "dts": {
    "inline": {
     "local": [
      "d60790d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "mtsr-20251103.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "mtsr-20251103_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mtsr-20251103_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-11-03_to_2025-11-03",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d60790d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-11-03_to_2025-11-03",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d60790d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://metsera.com//20251103/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-25-263828-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-263828-xbrl.zip
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M['OLL\B9)V[,/>$GD;MD$;! -%G2#*J#/P:$28-.Q?+"S">?P#@AX]Y2/YN
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M;PLXB[-%ZN#9 >[QY^,80,$R9M_?X3BV326>Z*?,5QEG@"#B&@)B[J$*M&B
M,,B.+*7SJPFXV1*S6& 5.A0$/XX=TCBHV+#'.E=XHMV&A:LD-4!SF#0"5PUF
MF9;F_1?=M]\[]^ R(\K@@F>J'-_U24Z[18XE #<H7R!BC8I@4\XS42<Q4B/<
MQV!G2IL3A8%R[83"PCI8L4I!O0&6 =>68@:!'**Y^<*A&2%6E=YJY.C=".L!
MW0+[_VM%D@79E765E7W"9I5\$)?0*SD\E?!!)_"1[=::AR_J^N.D O$K*D)R
M0O$-(0USS8DNYKB)IO0N/*Z7GLO1 MUIZ!2G1^S.R38"X+DM-B&%X7/V"V&I
MBD@ >ZQ1FJG&OV"UQ ;! +095:)Q8=!-[PXK%]D"$CV(A"GZ5"(UJ,\V<E*-
M''*6%PCE<;3P(ZD::6/WIBO.%7KI1(SD5S$"P1$><%QV-1*OH2?']W5Z'C)Z
MB3A3A/ AU"<:V O0AW"YA.Q7HG\![73! 4BV0$+)(F6,0U7<"> E#WM[(-,J
MFM50(JJ* DX,_@$+8!%"(8),Z%(_(H,FED&E_-INY56!T,=T&NP!]0(C&:.7
M P9B<1C+AQW.?PI55@7IK:U=D5,-]<&JG?I:UJP'LX$-L8J@G3_7ZT4I-!.V
MRKK"0Q5!N],4RX(4]SBF0.R 8[GB7FAXM-0C))HCQ A)R5DVGK#<IG.>J;Z2
MLI:$L^C8YJ.HFF-=!;YJY6]"!2!YKBZPA&\"A,2<O-TZ4U&(<?89Y'3%B(LN
M$08B(-$!*52PWT2 -7E4"03JR0HDVU#QK/$\/ 9,,S[.$^&T*[4K@+VH7K8,
MG*$N0!)!OA@T/L**))"3+#M6SU#/$6>@1F_G/R@>LYX">FTG\E;JA'"(3B<X
M%."#.A;6:U?*2M:M"]#.OA"O48$T?)Z],M+4*#!X:B8K6=<\3Y3[HA54PXS<
MKN@NG)PPM[A/3AUNA[C>DL6:#4\ B#>;L_;FD$Q%&DBYSR.0*_!U: ;.)O R
MWA=0$XJP*WV[D@E\S3JV7^$5%V;\2DR+Z^0$W \I;K<"DFWP!6:BK\CS1$<D
MS"1+I[MX[(;W +T%^H$$#*D:$SJG9D@QE<"XA&+5F[-)/( !.1HD]L_'VB<J
MDI51JP;4;CVDAQ";'01P*\4(M508I=BTP4C"[N2: :",$9$X%F*?$-XGG7'O
M.X/P&I5+C6GN-_9;4/RNV^(KY]3>1,,#FWF^][UX B?&:&B5@3["OA'KV'AI
MJZ).0P(E(K5>0AJU6@P)S9*L<1.G)?!H"8&M\P<.,Y=+0&<*>T<3L%%3A[D!
M%HK0P4+"I5)((VY4<8LU0FS38=G#MLD (A;$;97$?]?#_EA(7U?[>X*[Q("8
M [+FT'X.<4"\>?O\M7><=93)4LQ0FG:Y4&,#NL+1>?UACB^K0>./!EPN:&UQ
M ]\8C1\%8(5QM<Y@Y!B3(NZNL"NG%AP>$?P/139PH@PG/?!N%.JL>2,G351H
MGY"!Z)V 5R$S+0"A0:4 H-HM^RWJQ^7K6F&YG2V '#/3.=.B#6!NO4UH(1;N
M-@=AS(PKY5Q!M1@:2T$4!VV-E JPBC,&<H8AQ8]6&#C3!GM*58%%#>IH/%)5
M /:FEINKL6"9%N-^NP6*L8#4?C?)LB_(G ;:&V<5)CC ^:E5<:!(1P 4.$/V
MXO'%8FHZKHEQ[?N;2@RYSA6.HN)B<14A2--4-+>6#5+-_;#7&'29@5S]WKU1
MAK_0;MWQE;$RY2YP.DJD,38:N:"$A:D*=HSU9*(*VI0+?Q3QP(>Q36'+,"0K
M@D-!;$VP144XSV9R\"^H@,[)AT&N9*<%UJ/K)N;ZLNQMEN#D*6!"K!/2AG7U
M"QN+Y*!*C79)CT1L+02EP%]5@1\$0,EG$YBX%5R1M!$7>]0 ;;!2I\B$-9!I
M 009%'*'@6%77&^FH#'O\-LTR*J"6M'&&:*.CCWQ]M7;K006G%JM)L3+^-CV
M($)-<Q,R?/!832PP)#CM5PD%',LY@ &#3&&RP,0-G1;9BL]ZU!(N@*^!B3+R
M'C(@TN+"FCX0C^]I.@4"K_!%E;8];=>P3P3HN%%LLT_>M>_&L:HJ-1D@1%T&
M,W,-OMONS,RE!+8Z!CQ92'U;#QX$93?,'FV'?9N:BR<-%X!-LP2])SR:C2GR
MI@IS=EDL@Y$+.Q=P"];&+;.UIS@\\39*W((H&W4\Y)4-+T]=37#%6M6DP.(]
MSB.4&!I7G!6HAS%ZK!,<PO*UT(U'K*,P,$,=;GYZCF,$Z!I4R7YBXN#Q6%$K
MYY"%T6ZM2$.Z53(LV"9@%6NG<;[T;G_S#<?S-0>_HE?\\,"$W[C>YV@BC[+Q
M?<3N5@)U20/8;S/20]N]QQ$U3X<S%&4::X(34M."C@P>"]4&R][+0\0>1<4X
MQQ,<MC+FDD.C%0/Z2!T1UL@$EM!)I1K6F>6V*4;>-:$_$>HT8MIJ  Q$)4O8
M/W*C1)R)Z^D,W'%='8# #FX'/2[H.^Y)OL='&RIY1QI]%%"+[,+&4F(.<<1!
MTB0:%_R-;VF[613&\H6S5U/-Y_*^@.0\UJI/6G'S&[+O50?U#/TH\P^89&/3
M(?>:X"02SQM*)\H,?EZE7U)$?8EF/D*\J94#*0E# .\2#FE%[)-6K&?S2=?/
MX(1_:*7@E<&Q>"T6KAI4( N=QI4I"_#ZS,R.7PY2:9RWR^8ZP@"$)T)1-X]2
M>U@ A16.O]:U8*K?84H),(=K/H?;X$+("FK4D8WZ!554D0Y!G*#NCHM]J5IT
M\!5OB%7MCDCD H,TD\AC,@61'X'QU5]DP.XUF9Y"?^8?ZS#)7&6@<.1DW*1<
MIS/"9V+5+.O4+T] V0FH>3'P?"4@7M"4N2YME%X+<2L*W5@?U(4F<A'DQ1#T
MC H' ^F,*X^SA VQS#[2;JT^XU,N3.*2;(R@TE;O_/-1H6)T4.YUH! JO=5%
MEMIQ*EF ^S(!GW%>37E^4NN =0Q>V)01G:25O#\OF.W89MGT$"=PY&!6]6@J
MBS@H'MENMW/"U#V^-QG +59X5R]%D<(:]=J37L.-R2)-8FR,=J&]P/>HU-^$
MZE:FRK]M2M 45<_EN'0X15R$=25_)>/O"M/OR5$A-2O9*:WJ QB@!M-5'&9T
M@972@M2+YXQ0@M\L/G(%-K[!UA6"5=1M"ID0I7.;BB&"L5J$!>!8QTR<CRKA
MI9$:<:\_0J7R5?TC#;)NO_876,TL W^*$4CQ2;&.*R<*$ (I]#UZ[5D'=HT)
MC9U43!+(Z@N7"?E)=&()6SB$'EAL"I@!#)^8OD$> 59A2 V>VD&ACLV::%&%
M]020&T)-1A5\+HQ"2:(X ;6'7.(?I>*PC@*J6SJ.N V\14&J:)9F239=WA<.
M<&A$%I"N\OB1][.KX3@XWURILH&7G3Y!,$[C/(-=T/_2\$/DYQ/0%06I/)-*
M9UHM!P2>&K+X.<1:_T#C0S]''KL@B'LD$@X[<U\/[HNLHG30YRJ=R%L0/M9;
M(4[7I,#3TJI 0=+AVCT/A?NK0?6Y\?O;U(^N.6!RF*/-8B$6:,]8X(6>"WZV
M:4)-GEAR4!7K3A<7)KA"!0OEB(HY]E!-%L&^854>+QM<JR"F%Q8.+F:*CK?Y
M<U]8]DTM/A%7E1%_4FF3,;FM'+MT8=7'U'O1%-(,+XD4U=0U6IARF[YA[8@F
M_[%O\4L%;(FUA:.3]:BW 7VN!TN:DX?5ZB(%=AKMOAMHP^]2%6<#?2Z;YEK/
M9M;YNQ_(P5CE5.:%Q&D)\HQ=73RT,9M2R95RO21_[LBS"!R/5.,MGZQ6Y0+O
MK).79NA?(]FU)L"FI12F<3*B2U(TQ^O.V7$48&)E&>-9ZY2D,;97YY.'.-2H
M#?%O*[ML_04Y .X893?M!)&([QS0, *RUCI]EQH1:R A*WTGF4MZDD()>R]N
MJUC#+T+056L$<*5QLL-VZR[@5I>,[JVSGEY]&ISM[K\]=)53#CU4O*"D(02X
M77^3]<]L'@.X^)Q5OE<@L9\(@N/;I-H-FB+*FF94L6.5]04SYOJV5(G[^37_
M@P*$3X'#FK=MK8SK"S^V]X^%4W'.>_N+F_"<_?C<%NLO;;%^L#*:89\4(\(E
M8+T]INF<@B<.IY+;<BL_L9M'V!+PA#X-=[S!1C$HRQ!+9+5"6$*$(^3&%W^W
MK6U/_A1OC(57)6ARD)(F5(Q>FE;4T\UI]!7')N]3-NP+VKLX>[O_[O"?/U6
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MGO=!QN5I*J)_T<^Z']^<7K /,'P,O< =?HM!K=^Q9Z]7&OH8D?;W7J^(R9D
M#:YNNO>RO@GXL;D$U:SVH/5%G[KC^B9R$1]IVLD2#]!! :!=0,@, A-7SM;H
M1DQD&%E<O\&0#<GF(#RW3E;H<F,<,[QWD7(\H>0YW%]4*R#1#P$0&201,I"$
M^XB?D6I@B F(*HPSBC?4!G!MQ@( ;:GB$( :D'DF(R1B,&JZ<:0P:'L%6L+
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M;P-S_$HK72X;?8<ZK_W+TWV_5<4'1:J6Q]14I@R*(A#TB$P)_F,G^$I?I[!
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M1Q\+ZX"XNL0.&';8_-E&&4C.$F:8F-SCC[%BUMIQS,J4U056YM;1\F<SI:?
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M   -              "  0    !D-C W.3!D.&LN:'1M4$L! A0#%     @
M_55D6SM?;ZA,&0  55@  !               ( !3R4  &0V,#<Y,&1E>#DY
M,2YH=&U02P$"% ,4    " #]561;U6-L&HL0   ;2P  $
M@ ')/@  9#8P-SDP9&5X.3DR+FAT;5!+ 0(4 Q0    ( /U59%M,]L" .0,
M #L+   1              "  8)/  !M='-R+3(P,C4Q,3 S+GAS9%!+ 0(4
M Q0    ( /U59%NOH3;#J@8  *))   5              "  >I2  !M='-R
M+3(P,C4Q,3 S7VQA8BYX;6Q02P$"% ,4    " #]561;?Z8'Z]@$  #S+0
M%0              @ ''60  ;71S<BTR,#(U,3$P,U]P<F4N>&UL4$L%!@
0   &  8 ? $  -)>      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>d60790d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mtsr-20251103.xsd" xlink:type="simple"/>
    <context id="duration_2025-11-03_to_2025-11-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002040807</identifier>
        </entity>
        <period>
            <startDate>2025-11-03</startDate>
            <endDate>2025-11-03</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-448">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-11-03_to_2025-11-03"
      id="Hidden_dei_EntityCentralIndexKey">0002040807</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-459">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-460">2025-11-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-461">METSERA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-462">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-463">001-42489</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-464">92-0931552</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-465">3 World Trade Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-466">175 Greenwich Street</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-467">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-468">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-469">10007</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-470">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-471">784-6595</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-472">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-473">true</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-474">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-475">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-476">Common Stock, par value $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-477">MTSR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-478">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-479">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2025-11-03_to_2025-11-03" id="ixv-480">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
